TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences
H.C. Wainwright25th Annual Global Investment Conference– Available on demand beginning on September 11th at 7:00am EDT
- RW Baird 2023 Global Healthcare Conference –
September 12th at 4:20pm EDT
To access the H.C. Wainwright conference presentation, please visit the “Events and Presentations” page within the “Investors” section of the
TRACON is a clinical-stage biopharmaceutical company utilizing a cost-efficient, CRO-independent, product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1/2 development; and TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer. TRACON is actively seeking additional corporate partnerships through a profit-share or revenue-share partnership, or through franchising TRACON’s product development platform. TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States or who wish to become CRO-independent. To learn more about TRACON and its product pipeline, visit TRACON’s website at www.traconpharma.com.
|Company Contact:||Investor Contact:|
|Chief Executive Officer|
|(858) 550-0780||(212) 915-2578|
Source: TRACON Pharmaceuticals, Inc.